PDGFRB and hepatocellular carcinoma: Sorafenib can inhibit hepatocellular carcinoma growth by three mechanisms: blocking tumor cell proliferation via the MAPK pathway; inducing apoptosis by reducing survival factors; and decreasing tumor angiogenesis by inactivation of PDGFR‐β and VEGFR‐2/3.